Page 13 - Double Blind Study News Today

Phase 2b study data also showed a dose reduction in glucocorticoids among those who received the investigational drug compared with patients who received placebo.

New findings support starting tecovirimat treatment at the time of suspected mpox diagnosis in all people with HIV.

Novo Nordisk's CEO said on Tuesday he expects patients will stick with the company's popular obesity drug Wegovy for far longer than those using older...

Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big pharma's...

Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.

Its called lycopene. lycopene is clinically proven to help reduce your body fat and weight and to raise awareness about this weight loss breakthrough. the company is letting people try michaels lean risk free for 30 days. >> now you can four times more weight. just add life cuisine for only 2995. call right now and well double your order for free. ship it free to and for a limited time well double the size of each bottle for free. so now you have four times the low position for just 2995 . plus ...

Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to...

An analysis indicates that patients with fairly brisk walking are at a 24% lower risk for type 2 diabetes than those with easy or casual walking.

Promising preclinical and early clinical data suggest a role for GLP-1 receptor agonist therapy in treating alcohol use disorder.

Restarting a CGRP monoclonal antibody (mAb) after a gap in treatment may lower response rate, a new study suggests. However, switching to a different mAb may counter this effect.